期刊
JOURNAL OF EXPERIMENTAL MEDICINE
卷 215, 期 11, 页码 2833-2849出版社
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20180439
关键词
-
资金
- A*STAR
- Singapore Ministry of Health's National Medical Research Council Open Fund Individual Research Grants [NMRC/OFIRG/0023/2016]
- A*STAR Graduate Academy Singapore International Graduate Award scholarship
PTEN deficiency in breast cancer leads to resistance to PI3K-AKT inhibitor treatment despite aberrant activation of this signaling pathway. Here, we report that genetic depletion or small molecule inhibition of KDM4B histone demethylase activates the unfolded protein response (UPR) pathway and results in preferential apoptosis in PTEN-deficient triple-negative breast cancers (TNBCs). Intriguingly, this function of KDM4B on UPR requires its demethylase activity but is independent of its canonical role in histone modification, and acts through its cytoplasmic interaction with eIF2 alpha, a crucial component of UPR signaling, resulting in reduced phosphorylation of this component. Targeting KDM4B in combination with PI3K inhibition induces further activation of UPR, leading to robust synergy in apoptosis. These findings identify KDM4B as a therapeutic vulnerability in PTEN-deficient TNBC that otherwise would be resistant to PI3K inhibition.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据